Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic spontaneous urticaria for at least 6 months~* Diagnosis of chronic spontaneous urticaria refractory to standard of care at time of randomization~Exclusion Criteria:~* Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria~* Evidence of parasitic infection~* Any other skin disease with chronic itching~* Previous treatment with omalizumab or QGE031~* Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or epinephrine~* History of anaphylaxis~* History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study~* History of hypersensitivity to any of the study drugs or its components of similar chemical classes~* Pregnant or nursing (lactating) women~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- QGE031 24 mg s.c. q4w (Type: EXPERIMENTAL): ligelizumab 24 mg injection subcutaneous every 4 weeks
- QGE031 72 mg s.c. q4w (Type: EXPERIMENTAL): ligelizumab 72 mg injection subcutaneous every 4 weeks
- QGE031 240 mg s.c. q4w (Type: EXPERIMENTAL): ligelizumab 240 mg injection subcutaneous every 4 weeks
- Omalizumab 300 mg s.c. q4w (Type: ACTIVE_COMPARATOR): omalizumab 300 mg injection subcutaneous every 4 weeks
- Placebo s.c. q4w (Type: PLACEBO_COMPARATOR): placebo injection subcutaneous every 4 weeks
- QGE031 120 mg s.c. s.d. (Type: EXPERIMENTAL): ligelizumab 120 mg injection subcutaneous single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).